keyword
MENU ▼
Read by QxMD icon Read
search

Cancer autoantibody

keyword
https://www.readbyqxmd.com/read/28644254/sporadic-creutzfeldt-jakob-disease-with-unilateral-symptoms-in-the-setting-of-metastatic-renal-cell-carcinoma
#1
Kyle C Rossi, Christine M Stahl, Pengfei Zhang, John W Liang, Lara V Marcuse, Fred Lublin
INTRODUCTION: Although it is not rare for magnetic resonance imaging findings in Creutzfeldt-Jakob disease to be asymmetric, unilateral clinical syndromes are uncommonly reported and may confound diagnosis. In addition, neurological paraneoplastic syndromes are not common in renal cell carcinoma, though there are cases reported, often without an offending antibody isolated. CASE REPORT: A 66-year-old man was admitted with 1 month of left-sided numbness and "loss of control" of the left arm...
July 2017: Neurologist
https://www.readbyqxmd.com/read/28642817/cerebral-vasculitis-mimicking-intracranial-metastatic-progression-of-lung-cancer-during-pd-1-blockade
#2
Heinz Läubli, Jürgen Hench, Michal Stanczak, Ingmar Heijnen, Alexandros Papachristofilou, Stephan Frank, Alfred Zippelius, Frank Stenner-Liewen
BACKGROUND: Stimulation of the immune system by targeting the PD-1/PD-L1 pathway can result in activation of anti-tumor immunity. Besides its clinical benefit immune checkpoint therapy leads to significant immune-related adverse events (irAEs). Some rare irAEs are not well described yet but are critical in patient management. CASE PRESENTATION: Here, we describe a case of autoimmune cerebral vasculitis/encephalitis after PD-1 inhibitor treatment for metastatic adenocarcinoma of the lung...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28638733/identification-of-autoantibodies-to-ech1-and-hnrnpa2b1-as-potential-biomarkers-in-the-early-detection-of-lung-cancer
#3
Liping Dai, Jitian Li, Jun-Chieh J Tsay, Ting-An Yie, John S Munger, Harvey Pass, William N Rom, Eng M Tan, Jian-Ying Zhang
Identification of biomarkers for early detection of lung cancer (LC) is important, in turn leading to more effective treatment and reduction of mortality. Serological proteome analysis (SERPA) was used to identify proteins around 34 kD as ECH1 and HNRNPA2B1, which had been recognized by serum autoantibody from 25 LC patients. In the validation study, including 90 sera from LC patients and 89 sera from normal individuals, autoantibody to ECH1 achieved an area under the curve (AUC) of 0.799 with sensitivity of 62...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28638448/ratio-of-autoantibodies-of-tumor-suppressor-aimp2-and-its-oncogenic-variant-is-associated-with-clinical-outcome-in-lung-cancer
#4
Ji Ye Jung, Eun Young Kim, Arum Kim, Joon Chang, Nam Hoon Kwon, Youngji Moon, Eun Joo Kang, Jun Sik Sung, Hyunbo Shim, Sunghoon Kim, Yoon Soo Chang
Aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) works as potent tumor suppressor, while its splicing variant lacking exon 2 (AIMP2-DX2) competes with AIMP2 for binding to target proteins and compromises its anti-tumor activity. Assuming that AIMP2 and its variant AIMP2-DX2 could be released out to human sera in pathological condition, we investigated the diagnostic and prognostic usefulness of autoantibodies against AIMP2 and AIMP2-DX2 by measuring their serum levels in 80 normal and lung cancer samples that were matched in age, gender and smoking status...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28637689/elevation-of-tp53-autoantibody-prior-to-ca125-in-preclinical-invasive-epithelial-ovarian-cancer
#5
Wei-Lei Yang, Aleksandra Gentry-Maharaj, Archana R Simmons, Andy Ryan, Evangelia O Fourkala, Zhen Lu, Keith A Baggerly, Yang Zhao, Karen Lu, David D L Bowtell, Ian Jacobs, Steven J Skates, Wei-Wu He, Usha Menon, Robert C Bast
Purpose: The TP53 tumor suppressor gene is mutated in >95% of high grade serous ovarian cancers. Detecting an autologous antibody response to TP53 might improve early detection. <p>Experimental design: An immunoassay was developed to measure TP53 autoantibody in sera from 378 cases of invasive epithelial ovarian cancer and in 944 age-matched healthy controls from the United States, Australia and the United Kingdom. Serial preclinical samples from cases and controls were also assayed from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)...
June 21, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28631225/definition-of-the-upper-reference-limit-for-thyroglobulin-antibodies-according-to-the-national-academy-of-clinical-biochemistry-guidelines-comparison-of-eleven-different-automated-methods
#6
F D'Aurizio, P Metus, A Ferrari, B Caruso, R Castello, D Villalta, A Steffan, K Gaspardo, F Pesente, N Bizzaro, E Tonutti, S Valverde, C Cosma, M Plebani, R Tozzoli
PURPOSE: In the last two decades, thyroglobulin autoantibodies (TgAb) measurement has progressively switched from marker of thyroid autoimmunity to test associated with thyroglobulin (Tg) to verify the presence or absence of TgAb interference in the follow-up of patients with differentiated thyroid cancer. Of note, TgAb measurement is cumbersome: despite standardization against the International Reference Preparation MRC 65/93, several studies demonstrated high inter-method variability and wide variation in limits of detection and in reference intervals...
December 2017: Auto- Immunity Highlights
https://www.readbyqxmd.com/read/28628799/a-novel-2-stage-approach-that-detects-complement-activation-in-patients-with-antiphospholipid-antibody-syndrome
#7
Jacob H Rand, Xiao-Xuan Wu, Lucia R Wolgast, Victor Lei, Edward M Conway
INTRODUCTION: The antiphospholipid syndrome (APS) is marked by autoantibodies that recognize anionic phospholipids in a cofactor-dependent manner. A role for complement has been implicated in the pathophysiology, however, elevations of complement activation markers have not been consistently demonstrated in clinical studies. We therefore designed a proof-of-principle study to determine whether complement activation might be detectable in APS by first exposing plasmas to phospholipid vesicles...
June 9, 2017: Thrombosis Research
https://www.readbyqxmd.com/read/28628466/evaluation-of-cancer-associated-myositis-and-scleroderma-autoantibodies-in-breast-cancer-patients-without-rheumatic-disease
#8
Ami A Shah, Antony Rosen, Laura K Hummers, Betty J May, Alpana Kaushiva, Richard B S Roden, Deborah K Armstrong, Fredrick M Wigley, Livia Casciola-Rosen, Kala Visvanathan
OBJECTIVES: Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific autoantibodies in these diseases are markers of an increased risk of cancer at scleroderma and dermatomyositis onset, it is not known whether these autoantibodies are biomarkers of cancer risk in patients without rheumatic disease. METHODS: In a matched case-control study of women without rheumatic disease, identified from a familial breast cancer cohort, 50 breast cancer cases and 50 controls were assayed for 3 autoantibodies that are known markers of cancer-associated scleroderma and dermatomyositis: anti-RNA polymerase III, anti-NXP2, and anti-TIF1γ...
June 19, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28628235/expanded-phenotypes-and-outcomes-among-256-lgi1-caspr2-igg-positive-patients
#9
Avi Gadoth, Sean J Pittock, Divyanshu Dubey, Andrew McKeon, Jeff W Britton, John E Schmeling, Aurelia Smith, Amy L Kotsenas, Robert E Watson, Daniel H Lachance, Eoin P Flanagan, Vanda A Lennon, Christopher J Klein
OBJECTIVE: To describe an expanded phenotypic spectrum and longitudinal outcome in 256 LGI1-IgG or CASPR2-IgG seropositive patients. METHODS: Patients were identified through service neural autoantibody evaluation. Ninety-five had longitudinal follow-up (7-456 months; median 35). RESULTS: Among 3,910 patients tested, 196 were LGI1-IgG-positive; 51 were CASPR2-IgG-positive and 9 were dual-positive. CSF-testing was less sensitive than serum-testing, detecting only 24/38 LGI1-IgG-positive (63%) and 5/6 CASPR2-IgG-positive (83%)...
June 19, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28627551/gold-loaded-nanoporous-iron-oxide-nanocubes-a-novel-dispersible-capture-agent-for-tumor-associated-autoantibody-analysis-in-serum
#10
Sharda Yadav, Mostafa Kamal Masud, Md Nazmul Islam, Vinod Gopalan, Alfred King-Yin Lam, Shunsuke Tanaka, Nam-Trung Nguyen, Md Shahriar Al Hossain, Cuiling Li, Md Yusuke Yamauchi, Muhammad J A Shiddiky
Autoantibodies are produced against tumor associated antigens (TAAs) long before the appearance of any symptoms and thus can serve as promising, non-invasive biomarkers for early diagnosis of cancer. Current conventional methods for autoantibody detection are highly invasive and mostly provide diagnosis in the later stages of cancer. Herein we report a new electrochemical method for early detection of p53 autoantibodies against colon cancer using a strategy that combines the strength of gold-loaded nanoporous iron oxide nanocube (Au@NPFe2O3NC)-based capture and purification while incorporating the inherent simplicity, inexpensive, and portable nature of the electrochemical and naked-eye colorimetric readouts...
June 19, 2017: Nanoscale
https://www.readbyqxmd.com/read/28624156/a-noninvasive-blood-based-combinatorial-proteomic-biomarker-assay-to-detect-breast-cancer-in-women-under-the-age-of-50-years
#11
Ana P Lourenco, Kasey L Benson, Meredith C Henderson, Michael Silver, Elias Letsios, Quynh Tran, Kelly J Gordon, Sherri Borman, Christa Corn, Rao Mulpuri, Wendy Smith, Josie Alpers, Carrie Costantini, Nitin Rohatgi, Rebecca Yang, Ali Haythem, Shah Biren, Michael Morris, Fred Kass, David E Reese
BACKGROUND: Despite significant advances in breast imaging, the ability to detect breast cancer (BC) remains a challenge. To address the unmet needs of the current BC detection paradigm, 2 prospective clinical trials were conducted to develop a blood-based combinatorial proteomic biomarker assay (Videssa Breast) to accurately detect BC and reduce false positives (FPs) from suspicious imaging findings. PATIENTS AND METHODS: Provista-001 and Provista-002 (cohort one) enrolled Breast Imaging Reporting and Data System 3 or 4 women aged under 50 years...
May 23, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28618923/serum-autoantibodies-against-a-panel-of-15-tumor-associated-antigens-in-the-detection-of-ovarian-cancer
#12
Hao Sun, Jian-Xiang Shi, Hong-Fei Zhang, Meng-Tao Xing, Pei Li, Li-Ping Dai, Cheng-Lin Luo, Xiao Wang, Peng Wang, Hua Ye, Liu-Xia Li, Jian-Ying Zhang
In this study, enzyme-linked immunosorbent assay has been used to examine the frequencies of serum autoantibodies against two candidate tumor-associated antigens intensively selected from the Human Protein Atlas database, in combination with 13 tumor-associated antigens available from our lab in sera from 44 OC patients and 50 normal healthy controls. Conventional evaluation (mean + 3SD as the cutoff value to determine a positive reactivity), receiver operating characteristic curve analyses, and classification tree analysis were further used to evaluate the diagnostic performance of autoantibodies against these tumor-associated antigens (anti-tumor-associated antigens) in ovarian cancer...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28611636/autoimmune-diabetes-and-thyroiditis-complicating-treatment-with-nivolumab
#13
Li Li, Awais Masood, Shahla Bari, Sahzene Yavuz, Alan B Grosbach
Programmed cell death-1 (PD-1) ligand inhibitors have gained popularity in the treatment of advanced non-small-cell lung cancer. The immune system is regulated by stimulatory and inhibitory signaling and aims to achieve the balance between activation and inhibition. Treatment with immune checkpoint inhibitors enhances immune response, but is also known to diminish immune tolerance and increase autoimmune toxicity. Here we present a case of a patient with advanced squamous cell lung cancer who developed type I diabetes and thyroiditis after treatment with PD-1 checkpoint inhibitor nivolumab...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28609832/pembrolizumab-induced-thyroiditis-comprehensive-clinical-review-and-insights-into-underlying-involved-mechanisms
#14
Danae A Delivanis, Michael P Gustafson, Svetlana Bornschlegl, Michele M Merten, Lisa Kottschade, Sarah Withers, Allan B Dietz, Mabel Ryder
Context: Thyroid immune-related adverse events (irAEs) in patients treated with programmed death receptor-1 (PD-1) blockade are increasingly recognized as one of the most common adverse effects. Our aim was to determine the incidence and examine the potential mechanisms of anti-PD-1 induced thyroid irAEs. Design: Single center, retrospective cohort study. Patients and Measurements: We studied 93 patients with advanced cancer (aged 24–82 years; 60% males) who received at least one infusion of pembrolizumab...
May 9, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28601288/autoantibodies-as-diagnostic-biomarkers-for-the-detection-and-subtyping-of-multiple-sclerosis
#15
Cassandra DeMarshall, Eric L Goldwaser, Abhirup Sarkar, George A Godsey, Nimish K Acharya, Umashanger Thayasivam, Benjamin A Belinka, Robert G Nagele
The goal of this preliminary proof-of-concept study was to use human protein microarrays to identify blood-based autoantibody biomarkers capable of diagnosing multiple sclerosis (MS). Using sera from 112 subjects, including 51 MS subjects, autoantibody biomarkers effectively differentiated MS subjects from age- and gender-matched normal and breast cancer controls with 95.0% and 100% overall accuracy, but not from subjects with Parkinson's disease. Autoantibody biomarkers were also useful in distinguishing subjects with the relapsing-remitting form of MS from those with the secondary progressive subtype...
August 15, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/28588683/expression-and-immunogenicity-of-ny-eso-1-in-colorectal-cancer
#16
Ya Li, Ruifeng Song, Xinqiang Li, Feng Xu
Serum assays of NY-ESO-1 antibodies provide a guide to discriminate between patients who suffer from different types of cancer. In the present study, the expression of NY-ESO-1 was detected with the aim to identify a novel tumor antigen in colorectal cancer (CRC). Sera were obtained from 89 healthy individuals and 236 patients with CRC with stage I, II, III and IV tumors. The NY-ESO-1 autoantibody levels were determined using an enzyme-linked immunosorbent assay. The mRNA and protein expression levels of NY-ESO-1 were detected using reverse transcription-polymerase chain reaction and immunohistochemistry, respectively, in 60 CRC and paired adjacent non-tumor tissues...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28577954/recurrent-dysphasia-due-to-nivolumab-induced-encephalopathy-with-presence-of-hu-autoantibody
#17
Jo Raskin, Pegah Masrori, Antonin Cant, Annemie Snoeckx, Birgitta Hiddinga, Sisca Kohl, Annelies Janssens, Patrick Cras, Jan P Van Meerbeeck
A 58-year-old man was being treated for squamous non-small-cell lung cancer with nivolumab. At the 17th of biweekly administrations he presented with global dysphasia, dysarthria and myoclonus in the right upper extremity. MRI showed multiple T2/FLAIR hyperintense lesions in the left hemisphere; lumbar puncture showed lymphocytic pleiocytosis in the CSF without identifiable pathogens. Hu antibodies were present in serum and CSF. Nivolumab was discontinued and corticosteroids were administered. The neurological symptoms gradually improved; MRI showed complete remission of cerebral lesions...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28570322/autoimmune-neurology-of-the-central-nervous-system
#18
W Oliver Tobin, Sean J Pittock
PURPOSE OF REVIEW: This article reviews the rapidly evolving spectrum of autoimmune neurologic disorders with a focus on those that involve the central nervous system, providing an understanding of how to approach the diagnostic workup of patients presenting with central nervous system symptoms or signs that could be immune mediated, either paraneoplastic or idiopathic, to guide therapeutic decision making. RECENT FINDINGS: The past decade has seen a dramatic increase in the discovery of novel neural antibodies and their targets...
June 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/28564620/survivin-in-autoimmune-diseases
#19
REVIEW
G Gravina, C Wasén, M J Garcia-Bonete, M Turkkila, M C Erlandsson, S Töyrä Silfverswärd, M Brisslert, R Pullerits, K M Andersson, G Katona, M I Bokarewa
Survivin is a protein functionally important for cell division, apoptosis, and possibly, for micro-RNA biogenesis. It is an established marker of malignant cell transformation. In non-malignant conditions, the unique properties of survivin make it indispensable for homeostasis of the immune system. Indeed, it is required for the innate and adaptive immune responses, controlling differentiation and maintenance of CD4(+) and CD8(+) memory T-cells, and in B cell maturation. Recently, survivin has emerged as an important player in the pathogenesis of autoimmune diseases...
May 28, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28554330/rho-associated-protein-kinase-2-rock2-a-new-target-of-autoimmunity-in-paraneoplastic-encephalitis
#20
Stoyan Popkirov, Ilya Ayzenberg, Stefanie Hahn, Jan Bauer, Yvonne Denno, Nicole Rieckhoff, Christiane Radzimski, Volkmar H Hans, Sebastian Berg, Florian Roghmann, Joachim Noldus, Christian G Bien, Sabine Skodda, Jörg Wellmer, Winfried Stöcker, Christos Krogias, Ralf Gold, Uwe Schlegel, Christian Probst, Lars Komorowski, Ramona Miske, Ingo Kleiter
Onconeural antibodies are associated with cancer and paraneoplastic encephalitis. While their pathogenic role is still largely unknown, their high diagnostic value is undisputed. In this study we describe the discovery of a novel target of autoimmunity in an index case of paraneoplastic encephalitis associated with urogenital cancer.A 75-year-old man with a history of invasive bladder carcinoma 6 years ago with multiple recurrences and a newly discovered renal cell carcinoma presented with seizures and progressive cognitive decline followed by super-refractory status epilepticus...
May 29, 2017: Acta Neuropathologica Communications
keyword
keyword
99523
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"